Cite

HARVARD Citation

    Liu, G. et al. (2022). A novel combination of niraparib and anlotinib in platinum-resistant ovarian cancer: Efficacy and safety results from the phase II, multi-center ANNIE study. EClinicalMedicine. p. . [Online]. 
  
Back to record